Hemagen Diagnostics Inc represents a commitment to delivering reliable diagnostic solutions and improving patient care. The company values innovation and strives to develop cutting-edge technologies in the field of diagnostics. With a focus on accuracy and efficiency, Hemagen Diagnostics Inc aims to provide healthcare professionals with accurate and timely test results. The company's corporate philosophy revolves around integrity, customer satisfaction, and collaboration with healthcare providers. Hemagen Diagnostics Inc is dedicated to making a positive impact in the medical industry by offering high-quality diagnostic products and fulfilling the evolving needs of the market.

Hemagen Diagnostics Inc is primarily present in the United States.

Hemagen Diagnostics Inc has achieved several significant milestones since its establishment. The company has made notable strides in the field of diagnostics, particularly in the development of advanced laboratory tests and technologies. Hemagen Diagnostics Inc has successfully introduced innovative solutions that enhance the accuracy and efficiency of diagnostic processes. Through their commitment to research and development, the company has also expanded its product portfolio, catering to various medical needs. Continuously striving for excellence, Hemagen Diagnostics Inc has gained recognition for its contributions in the healthcare industry and remains dedicated to providing reliable diagnostic solutions to healthcare professionals and patients worldwide.

Hemagen Diagnostics Inc is a renowned company in the field of medical diagnostics. Founded in 1985, Hemagen has been dedicated to providing innovative diagnostic solutions to the healthcare industry. With its headquarters in Columbia, Maryland, the company has gained a strong presence in the market over the years. Hemagen specializes in developing and manufacturing cutting-edge diagnostic tests for various medical conditions, including infectious diseases, autoimmune disorders, and cancer. Their commitment to delivering accurate and reliable results has garnered them a loyal customer base. Hemagen Diagnostics Inc continues to strive for excellence in medical diagnostics, positioning itself as a trusted name in the industry.

Some of the main competitors of Hemagen Diagnostics Inc in the market include companies like Abbott Laboratories, Thermo Fisher Scientific, Roche Diagnostics, Bio-Rad Laboratories, and Siemens Healthineers.

Hemagen Diagnostics Inc primarily operates in the healthcare industry.

The business model of Hemagen Diagnostics Inc. focuses on the development, manufacturing, and distribution of innovative diagnostic products and services. Hemagen Diagnostics Inc. specializes in providing cutting-edge medical technologies for the healthcare industry. By leveraging their expertise in diagnostics, Hemagen Diagnostics Inc. aims to improve patient outcomes by providing accurate and timely diagnostic solutions. Through their wide range of products, Hemagen Diagnostics Inc. caters to various healthcare settings, including hospitals, laboratories, and physicians' offices. With a commitment to research and development, Hemagen Diagnostics Inc. continually strives to introduce new and advanced diagnostic solutions to meet the evolving needs of the medical community.

KGV za Hemagen Diagnostics trenutno ne može biti izračunato.

KUV za Hemagen Diagnostics trenutno ne može biti izračunat.

AlleAktien kvalitativni skor za Hemagen Diagnostics je 3/10.

Prihod trenutno ne može biti izračunat za Hemagen Diagnostics.

Profit trenutno ne može biti izračunat za Hemagen Diagnostics.

Hemagen Diagnostics is an In-Vitro Diagnostics manufacturer based in New Jersey since 1985. The company offers a wide range of tests for diseases and blood disorders. Thanks to its extensive experience and innovative diagnostic technologies, Hemagen Diagnostics is a leader in the world of IVD medicine. Hemagen Diagnostics operates globally and has customers in over 50 countries. The company conducts its business in three main divisions: Specialty Laboratories, Medical Technology, and Global Markets. The Specialty Laboratories are responsible for manufacturing blood products and diagnostic reagents for hospitals and clinics. The Medical Technology division is in charge of commercializing and distributing products for rapid diagnostics of blood disorders and pregnancy tests. Finally, the Global Markets division is responsible for selling products in countries outside the USA. Hemagen Diagnostics produces a wide range of products for various applications, including blood tests for anemia, hemoglobinopathies, and severe infectious diseases. The products range from simple rapid tests to complex blood screenings for hospitals and medical laboratories. A core product of Hemagen Diagnostics is the supplied ELISA test for identification and quantification of human proteins. The company also offers an innovative laboratory system for automated testing, which significantly improves time management for medical professionals and laboratories. Another important product line of Hemagen Diagnostics includes tests for chronic lymphocytic leukemia (CLL) and malignant lymphomas, which were developed in collaboration with Accumen Diagnostics. These tests use proprietary technologies to enhance the diagnosis and treatment processes for these challenging diseases. Hemagen Diagnostics is committed to providing the latest technologies and methods for IVD medicine. The company is constantly seeking new opportunities for innovation and efficiency optimization to succeed in a rapidly changing world of clinical diagnostics. Overall, Hemagen Diagnostics' business model is designed for long-term success in a challenging and expanding industry. The three divisions of the company enable a wide range of products and offer a variety of opportunities for customers and relationships worldwide.

Hemagen Diagnostics isplaćuje dividendu od 0 USD raspoređenu preko isplata u toku godine.

Dividenda za Hemagen Diagnostics trenutno ne može biti izračunata ili kompanija ne isplaćuje dividendu.

ISIN od Hemagen Diagnostics je US4235011057.

WKN od Hemagen Diagnostics je 885724.

Oznaka za praćenje akcija kompanije Hemagen Diagnostics je HMGN.

U poslednjih 12 meseci, Hemagen Diagnostics je isplatio dividendu u iznosu od . To odgovara dividendnom prinosu od oko . Za narednih 12 meseci, Hemagen Diagnostics će verovatno isplatiti dividendu od 0 USD.

Dividendski prinos od Hemagen Diagnostics trenutno iznosi .

Hemagen Diagnostics isplaćuje dividende na kvartalnom nivou. One se isplaćuju u mesecima .

Hemagen Diagnostics je isplaćivao dividendu svake godine u poslednjih 0 godina.

Za narednih 12 meseci očekuju se dividende u iznosu od 0 USD. To odgovara dividendnom prinosu od 0 %.

Hemagen Diagnostics se svrstava u sektor 'Zdravlje'.

Da biste primili poslednju dividendu od Hemagen Diagnostics od 1. 10. 2024. u iznosu od 0 USD, morali ste da imate akciju u depou pre Ex-dana 1. 10. 2024..

Isplata poslednje dividende izvršena je 1. 10. 2024..

U godini 2023 kompanija Hemagen Diagnostics je isplatila 0 USD kao dividende.

Dividende od Hemagen Diagnostics se isplaćuju u USD.